Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity

Patrick A Flume, James D Chalmers, Kenneth N Olivier, Patrick A Flume, James D Chalmers, Kenneth N Olivier

Abstract

Bronchiectasis is characterised by pathological dilation of the airways. More specifically, the radiographic demonstration of airway enlargement is the common feature of a heterogeneous set of conditions and clinical presentations. No approved therapies exist for the condition other than for bronchiectasis caused by cystic fibrosis. The heterogeneity of bronchiectasis is a major challenge in clinical practice and the main reason for difficulty in achieving endpoints in clinical trials. Recent observations of the past 2 years have improved the understanding of physicians regarding bronchiectasis, and have indicated that it might be more effective to classify patients in a different way. Patients could be categorised according to a heterogeneous group of endotypes (defined by a distinct functional or pathobiological mechanism) or by clinical phenotypes (defined by relevant and common features of the disease). In doing so, more specific therapies needed to effectively treat patients might finally be developed. Here, we describe some of the recent advances in endotyping, genetics, and disease heterogeneity of bronchiectasis including observations related to the microbiome.

Conflict of interest statement

Conflict of Interest Statement

PAF has research grants with Bayer Healthcare AG, Corbus Pharmaceuticals, Cystic Fibrosis Foundation Therapeutics, Galapagos, Insmed Inc, National Institutes of Health, Novartis, Novoteris, Pro-QR, Proteostasis Therapeutics, Sound Pharmaceuticals, Inc, Vertex Pharmaceuticals, Inc and has served as a consultant to Bayer Healthcare AG, Corbus Pharmaceuticals, Horizon Pharma, Insmed Inc, McKesson, Novartis, Protalix, Proteostasis Therapeutics, Vertex Pharmaceuticals, Inc. JDC has research grants with Astrazeneca, Boehringer-Ingelheim, Glaxosmithkline, Grifols, Bayer. KNO’s former employer, NIAID, had a Cooperative Research and Development Agreement with Insmed, Inc, and his current employer, NHLBI, has Research Agreements with AIT Therapeutics, Inc.

Copyright © 2018 Elsevier Ltd. All rights reserved.

Figures

Figure 1.. Model describing the pathogenesis of…
Figure 1.. Model describing the pathogenesis of bronchiectasis.
A cycle of events that promote a persistent and progressive process over time. Impaired mucociliary clearance and retention of airways phlegm disrupt normal host defenses, renderings the airways vulnerable to infection, which can become persistent. This, in turn, incites an inflammatory response causing injury and abnormal remodeling of the airways leading to bronchiectasis.
Figure 2.. CFTR mutation classification.
Figure 2.. CFTR mutation classification.
Cystic fibrosis transmembrane conductance regulators (CFTR) mutation classification based on molecular defect. These molecular defects correspond to therapeutic approaches to restore the quantity of protein and/or its function resulting in genotype specific CFTR modulator drugs used alone (ivacaftor) or in combination (lumacaftor/ivacaftor, tezacaftor/ivacaftor). Adapted from
Figure 3.. Ciliary dyskinesia gene classifications.
Figure 3.. Ciliary dyskinesia gene classifications.
Defects in cilia genes can be classified based on ultrastructural effects seen on cross sectional examination of cilia with electron microscopy. Note that some genes can be mutated without obvious structural abnormalities. Adapted from
Figure 4.. Potential endotypes for idiopathic bronchiectasis…
Figure 4.. Potential endotypes for idiopathic bronchiectasis patients with pulmonary NTM infections.
Characterization with biomarker measurements of sweat chloride, nasal NO, ciliary beat frequency, and body morphometrics coupled with the presence of relevant genetic variants may allow therapeutic targeting based on predominant endotype. Examples would be the potential use of CFTR modulators in patients that have a CF-predominant endotype , sildenafil or other nitric oxide pathway agonists for cilia-predominant endotype , TGF-beta attenuators such as losartan for heritable connective tissue-predominant endotype , and immune modulators such as GMCSF for immune deficient predominant endotype

References

    1. Chalmers JD, Aliberti S, Blasi F. Management of bronchiectasis in adults. The European respiratory journal. 2015; 45(5): 1446–62.
    1. Araujo D, Shteinberg M, Aliberti S, Goeminne PC, Hill AT, Fardon T, et al. Standardised classification of the aetiology of bronchiectasis using an objective algorithm. The European respiratory journal. 2017; 50(6): 1701289.
    1. Spinou A, Siegert RJ, Guan WJ, Patel AS, Gosker HR, Lee KK, et al. The development and validation of the Bronchiectasis Health Questionnaire. The European respiratory journal. 2017; 49(5): 1601532.
    1. Quint JK, Millett ER, Joshi M, Navaratnam V, Thomas SL, Hurst JR, et al. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study. The European respiratory journal. 2016; 47(1): 186–93.
    1. Polverino E, Goeminne PC, McDonnell MJ, Aliberti S, Marshall SE, Loebinger MR, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. The European respiratory journal. 2017; 50(3): 1700629.
    1. Nadig TR, Flume PA. Aerosolized Antibiotics for Patients with Bronchiectasis. Am J Respir Crit Care Med. 2016; 193(7): 808–10.
    1. Serisier DJ, Martin ML, McGuckin MA, Lourie R, Chen AC, Brain B, et al. Effect of long-term, low- dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA. 2013; 309(12): 1260–7.
    1. Aksamit T, De Soyza A, Bandel TJ, Criollo M, Elborn JS, Operschall E, et al. RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. The European respiratory journal. 2018; 51(1): 1702053.
    1. De Soyza A, Aksamit T, Bandel TJ, Criollo M, Elborn JS, Operschall E, et al. RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. The European respiratory journal. 2018; 51(1): 1702052.
    1. Anderson GP. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet. 2008; 372(9643): 1107–19.
    1. Han MK, Agusti A, Calverley PM, Celli BR, Criner G, Curtis JL, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med. 2010; 182(5): 598–604.
    1. Chapin HC, Caplan MJ. The cell biology of polycystic kidney disease. The Journal of cell biology. 2010; 191(4): 701–10.
    1. Driscoll JA, Bhalla S, Liapis H, Ibricevic A, Brody SL. Autosomal dominant polycystic kidney disease is associated with an increased prevalence of radiographic bronchiectasis. Chest 2008; 133(5): 1181–8.
    1. Gilley SK, Stenbit AE, Pasek RC, Sas KM, Steele SL, Amria M, et al. Deletion of airway cilia results in noninflammatory bronchiectasis and hyperreactive airways. Am J Physiol Lung Cell Mol Physiol. 2014; 306(2): L162–9.
    1. Svenningsen S, Nair P. Asthma Endotypes and an Overview of Targeted Therapy for Asthma. Front Med (Lausanne). 2017; 4: 10.
    1. Rommens JM, Iannuzzi MC, Kerem B, Drumm ML, Melmer G, Dean M, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science. 1989; 245(4922): 1059–65.
    1. Welsh MJ, Smith AE. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell. 1993; 73(7): 1251–4.
    1. Sheikh SI, Long FR, McCoy KS, Johnson T, Ryan-Wenger NA, Hayes D Jr., Computed tomography correlates with improvement with ivacaftor in cystic fibrosis patients with G551D mutation. J Cyst Fibros. 2015; 14(1): 84–9.
    1. Heltshe SL, Mayer-Hamblett N, Burns JL, Khan U, Baines A, Ramsey BW, et al. Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2015; 60(5): 703–12.
    1. Shapiro AJ, Josephson M, Rosenfeld M, Yilmaz O, Davis SD, Polineni D, et al. Accuracy of Nasal Nitric Oxide Measurement as a Diagnostic Test for Primary Ciliary Dyskinesia. A Systematic Review and Meta-analysis. Annals of the American Thoracic Society. 2017; 14(7): 1184–96.
    1. Shoemark A, Moya E, Hirst RA, Patel MP, Robson EA, Hayward J, et al. High prevalence of CCDC103 p.His154Pro mutation causing primary ciliary dyskinesia disrupts protein oligomerisation and is associated with normal diagnostic investigations. Thorax. 2018; 73(2): 157–66.
    1. Fowler CJ, Olivier KN, Leung JM, Smith CC, Huth AG, Root H, et al. Abnormal nasal nitric oxide production, ciliary beat frequency, and Toll-like receptor response in pulmonary nontuberculous mycobacterial disease epithelium. Am J Respir Crit Care Med. 2013; 187(12): 1374–81.
    1. Horani A, Ferkol TW, Dutcher SK, Brody SL. Genetics and biology of primary ciliary dyskinesia. Paediatric respiratory reviews. 2016; 18: 18–24.
    1. Buckley RH. Pulmonary complications of primary immunodeficiencies. Paediatric respiratory reviews. 2004; 5 Suppl A: S225–33.
    1. Ameratunga R, Lehnert K, Woon ST, Gillis D, Bryant VL, Slade CA, et al. Review: Diagnosing Common Variable Immunodeficiency Disorder in the Era of Genome Sequencing. Clinical reviews in allergy & immunology. 2018; 54(2): 261–8.
    1. Vetrie D, Vorechovsky I, Sideras P, Holland J, Davies A, Flinter F, et al. The gene involved in X- linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature. 1993; 361(6409): 226–33.
    1. Broides A, Yang W, Conley ME. Genotype/phenotype correlations in X-linked agammaglobulinemia. Clin Immunol. 2006; 118(2–3): 195–200.
    1. Holland SM, DeLeo FR, Elloumi HZ, Hsu AP, Uzel G, Brodsky N, et al. STAT3 mutations in the hyper-IgE syndrome. N Engl J Med. 2007; 357(16): 1608–19.
    1. Minegishi Y, Saito M, Nagasawa M, Takada H, Hara T, Tsuchiya S, et al. Molecular explanation for the contradiction between systemic Th17 defect and localized bacterial infection in hyper-IgE syndrome. J Exp Med. 2009; 206(6): 1291–301.
    1. Hsu AP, Pittaluga S, Martinez B, Rump AP, Raffeld M, Uzel G, et al. IL2RG reversion event in a common lymphoid progenitor leads to delayed diagnosis and milder phenotype. J Clin Immunol. 2015; 35(5): 449–53.
    1. Coulter TI, Chandra A, Bacon CM, Babar J, Curtis J, Screaton N, et al. Clinical spectrum and features of activated phosphoinositide 3-kinase delta syndrome: A large patient cohort study. The Journal of allergy and clinical immunology. 2017; 139(2): 597–606 e4.
    1. Egan JP, 3rd, Seides BJ, Olivier KN, Addrizzo-Harris D. Successful treatment of ulcerative bronchiolitis in a woman with refractory Mycobacterium intracellulare infection. BMJ Case Rep. 2015; 2015: bcr2015209604.
    1. Ye BD, McGovern DP. Genetic variation in IBD: progress, clues to pathogenesis and possible clinical utility. Expert Rev Clin Immunol. 2016; 12(10): 1091–107.
    1. Agarwal R, Aggarwal AN, Dhooria S, Singh Sehgal I, Garg M, Saikia B, et al. A randomised trial of glucocorticoids in acute-stage allergic bronchopulmonary aspergillosis complicating asthma. The European respiratory journal. 2016; 47(2): 490–8.
    1. Agarwal R, Chakrabarti A, Shah A, Gupta D, Meis JF, Guleria R, et al. Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. Clin Exp Allergy. 2013; 43(8): 850–73.
    1. Overton NL, Denning DW, Bowyer P, Simpson A. Genetic susceptibility to allergic bronchopulmonary aspergillosis in asthma: a genetic association study. Allergy Asthma Clin Immunol. 2016; 12: 47.
    1. Blasi F, Chalmers JD, Aliberti S. COPD and bronchiectasis: phenotype, endotype or co-morbidity? COPD. 2014; 11(6): 603–4.
    1. Hurst JR, Elborn JS, De Soyza A. COPD-bronchiectasis overlap syndrome. The European respiratory journal. 2015; 45(2): 310–3.
    1. Mao B, Yang JW, Lu HW, Xu JF. Asthma and bronchiectasis exacerbation. The European respiratory journal. 2016; 47(6): 1680–6.
    1. Prince DS, Peterson DD, Steiner RM, Gottlieb JE, Scott R, Israel HL, et al. Infection with Mycobacterium avium complex in patients without predisposing conditions. N Engl J Med. 1989; 321(13): 863–8.
    1. Reich JM, Johnson RE. Mycobacterium avium complex pulmonary disease presenting as an isolated lingular or middle lobe pattern. The Lady Windermere syndrome. Chest. 1992; 101(6): 1605–9.
    1. Ziedalski TM, Kao PN, Henig NR, Jacobs SS, Ruoss SJ. Prospective analysis of cystic fibrosis transmembrane regulator mutations in adults with bronchiectasis or pulmonary nontuberculous mycobacterial infection. Chest. 2006; 130(4): 995–1002.
    1. Kim RD, Greenberg DE, Ehrmantraut ME, Guide SV, Ding L, Shea Y, et al. Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. Am J Respir Crit Care Med. 2008; 178(10): 1066–74.
    1. Daniels ML, Birchard KR, Lowe JR, Patrone MV, Noone PG, Knowles MR. Enlarged Dural Sac in Idiopathic Bronchiectasis Implicates Heritable Connective Tissue Gene Variants. Annals of the American Thoracic Society. 2016; 13(10): 1712–20.
    1. Leung JM, Olivier KN, Prevots DR, McDonnell NB. Beyond Marfan: the clinical impact of bronchiectasis and non-tuberculous mycobacteria in connective tissue diseases. Int J Tuberc Lung Dis. 2015; 19(11): 1409.
    1. Szymanski EP, Leung JM, Fowler CJ, Haney C, Hsu AP, Chen F, et al. Pulmonary Nontuberculous Mycobacterial Infection. A Multisystem, Multigenic Disease. Am J Respir Crit Care Med. 2015; 192(5): 618–28.
    1. McDonnell MJ, Aliberti S, Goeminne PC, Dimakou K, Zucchetti SC, Davidson J, et al. Multidimensional severity assessment in bronchiectasis: an analysis of seven European cohorts. Thorax. 2016; 71(12): 9.
    1. Lonni S, Chalmers JD, Goeminne PC, McDonnell MJ, Dimakou K, De Soyza A, et al. Etiology of Non-Cystic Fibrosis Bronchiectasis in Adults and Its Correlation to Disease Severity. Annals of the American Thoracic Society. 2015; 12(12): 1764–70.
    1. Shoemark A, Ozerovitch L, Wilson R. Aetiology in adult patients with bronchiectasis. Respiratory medicine. 2007; 101(6): 1163–70.
    1. McShane PJ, Naureckas ET, Strek ME. Bronchiectasis in a diverse US population: effects of ethnicity on etiology and sputum culture. Chest. 2012; 142(1): 159–67.
    1. Chalmers JD, Chotirmall SH. New therapies and new perspectives. Lancet Respir Med. 2018; in press.
    1. Hill AT, Haworth CS, Aliberti S, Barker A, Blasi F, Boersma W, et al. Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research. The European respiratory journal. 2017; 49(6).
    1. Chalmers JD, Aliberti S, Filonenko A, Shteinberg M, Goeminne PC, Hill AT, et al. Characterisation of the “Frequent Exacerbator Phenotype” in Bronchiectasis. Am J Respir Crit Care Med. 2018; 197(11): 11.
    1. Hurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010; 363(12): 1128–38.
    1. VanDevanter DR, Morris NJ, Konstan MW. IV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosis. J Cyst Fibros. 2016; 15(3): 372–9.
    1. Aliberti S, Lonni S, Dore S, McDonnell MJ, Goeminne PC, Dimakou K, et al. Clinical phenotypes in adult patients with bronchiectasis. The European respiratory journal. 2016; 47(4): 1113–22.
    1. Guan WJ, Jiang M, Gao YH, Li HM, Xu G, Zheng JP, et al. Unsupervised learning technique identifies bronchiectasis phenotypes with distinct clinical characteristics. Int J Tuberc Lung Dis. 2016; 20(3): 402–10.
    1. Finch S, McDonnell MJ, Abo-Leyah H, Aliberti S, Chalmers JD. A Comprehensive Analysis of the Impact of Pseudomonas aeruginosa Colonization on Prognosis in Adult Bronchiectasis. Annals of the American Thoracic Society. 2015; 12(11): 1602–11.
    1. Loebinger MR, Wells AU, Hansell DM, Chinyanganya N, Devaraj A, Meister M, et al. Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. The European respiratory journal. 2009; 34(4): 843–9.
    1. Araujo D, Shteinberg M, Aliberti S, Goeminne PC, Hill AT, Fardon TC, et al. The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis. The European respiratory journal. 2018; 51(2).
    1. Hilliam Y, Moore MP, Lamont IL, Bilton D, Haworth CS, Foweraker J, et al. Pseudomonas aeruginosa adaptation and diversification in the non-cystic fibrosis bronchiectasis lung. The European respiratory journal. 2017; 49(4).
    1. Frija-Masson J, Martin C, Regard L, Lothe MN, Touqui L, Durand A, et al. Bacteria-driven peribronchial lymphoid neogenesis in bronchiectasis and cystic fibrosis. The European respiratory journal. 2017; 49(4).
    1. Nair C, Shoemark A, Chan M, Ollosson S, Dixon M, Hogg C, et al. Cyanide levels found in infected cystic fibrosis sputum inhibit airway ciliary function. The European respiratory journal. 2014; 44(5): 1253–61.
    1. Wall C, Hoyle JC. Observations on DRY BRONCHIECTASIS. Br Med J. 1933; 1(3770): 597–620.
    1. Smith DJ. Phenotyping bronchiectasis: is it all about sputum and infection? The European respiratory journal. 2016; 47(4): 1037–9.
    1. Camus P, Colby TV. Bronchiectasis associated with inflammatory bowel disease. Eur Respir Mon. 2011; 52: 163–77.
    1. Vallieres E, Tumelty K, Tunney MM, Hannah R, Hewitt O, Elborn JS, et al. Efficacy of Pseudomonas aeruginosa eradication regimens in bronchiectasis. The European respiratory journal. 2017; 49(4).
    1. Chalmers JD, Goeminne P, Aliberti S, McDonnell MJ, Lonni S, Davidson J, et al. The bronchiectasis severity index. An international derivation and validation study. Am J Respir Crit Care Med. 2014; 189(5): 576–85.
    1. Aksamit TR, O’Donnell AE, Barker A, Olivier KN, Winthrop KL, Daniels MLA, et al. Adult Patients With Bronchiectasis: A First Look at the US Bronchiectasis Research Registry. Chest. 2017; 151(5): 982–92.
    1. Faner R, Sibila O, Agusti A, Bernasconi E, Chalmers JD, Huffnagle GB, et al. The microbiome in respiratory medicine: current challenges and future perspectives. The European respiratory journal. 2017; 49(4).
    1. Tunney MM, Einarsson GG, Wei L, Drain M, Klem ER, Cardwell C, et al. Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation. Am J Respir Crit Care Med. 2013; 187(10): 1118–26.
    1. Rogers GB, van der Gast CJ, Cuthbertson L, Thomson SK, Bruce KD, Martin ML, et al. Clinical measures of disease in adult non-CF bronchiectasis correlate with airway microbiota composition. Thorax. 2013; 68(8): 731–7.
    1. Cox MJ, Turek EM, Hennessy C, Mirza GK, James PL, Coleman M, et al. Longitudinal assessment of sputum microbiome by sequencing of the 16S rRNA gene in non-cystic fibrosis bronchiectasis patients. PloS one. 2017; 12(2): e0170622.
    1. Chalmers JD, Moffitt KL, Suarez-Cuartin G, Sibila O, Finch S, Furrie E, et al. Neutrophil Elastase Activity Is Associated with Exacerbations and Lung Function Decline in Bronchiectasis. Am J Respir Crit Care Med. 2017; 195(10): 1384–93.
    1. Taylor SL, Rogers GB, Chen AC, Burr LD, McGuckin MA, Serisier DJ. Matrix metalloproteinases vary with airway microbiota composition and lung function in non-cystic fibrosis bronchiectasis. Annals of the American Thoracic Society. 2015; 12(5): 701–7.
    1. Rogers GB, Zain NM, Bruce KD, Burr LD, Chen AC, Rivett DW, et al. A novel microbiota stratification system predicts future exacerbations in bronchiectasis. Annals of the American Thoracic Society. 2014; 11(4): 496–503.
    1. Ishak A, Everard ML. Persistent and Recurrent Bacterial Bronchitis-A Paradigm Shift in Our Understanding of Chronic Respiratory Disease. Frontiers in pediatrics. 2017; 5: 9.
    1. Metersky ML, Mangardich A. Chronic suppurative lung disease in adults. Journal of thoracic disease. 2016; 8(9): E974–E8.
    1. Hughes DT, Sperandio V. Inter-kingdom signalling: communication between bacteria and their hosts. Nature reviews Microbiology. 2008; 6(2): 111–20.
    1. Rogers GB, Bruce KD, Martin ML, Burr LD, Serisier DJ. The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial. Lancet Respir Med. 2014; 2(12): 988–96.
    1. Mac Aogain M, Chandrasekaran R, Lim Yick Hou A, Teck Boon L, Liang Tan G, Hassan T, et al. Immunological Corollary of the Pulmonary Mycobiome in Bronchiectasis: The Cameb Study. The European respiratory journal. 2018.
    1. Caverly LJ, Carmody LA, Haig SJ, Kotlarz N, Kalikin LM, Raskin L, et al. Culture-Independent Identification of Nontuberculous Mycobacteria in Cystic Fibrosis Respiratory Samples. PloS one. 2016; 11(4): e0153876.
    1. Aliberti S, Masefield S, Polverino E, De Soyza A, Loebinger MR, Menendez R, et al. Research priorities in bronchiectasis: a consensus statement from the EMBARC Clinical Research Collaboration. The European respiratory journal. 2016; 48(3): 632–47.
    1. Lopes-Pacheco M CFTR Modulators: Shedding Light on Precision Medicine for Cystic Fibrosis. Front Pharmacol. 2016; 7: 275.
    1. Horani A, Ferkol TW. Primary ciliary dyskinesia and associated sensory ciliopathies. Expert Rev Respir Med. 2016; 10(5): 569–76.
    1. Solomon GM, Fu L, Rowe SM, Collawn JF. The therapeutic potential of CFTR modulators for COPD and other airway diseases. Current opinion in pharmacology. 2017; 34: 132–9.
    1. Loeys BL. Angiotensin receptor blockers: a panacea for Marfan syndrome and related disorders? Drug discovery today. 2015; 20(2): 262–6.
    1. Scott JP, Ji Y, Kannan M, Wylam ME. Inhaled granulocyte-macrophage colony-stimulating factor for Mycobacterium abscessus in cystic fibrosis. The European respiratory journal. 2018; 51(4).
    1. De Soyza A, McDonnell MJ, Goeminne PC, Aliberti S, Lonni S, Davison J, et al. Bronchiectasis Rheumatoid Overlap Syndrome Is an Independent Risk Factor for Mortality in Patients With Bronchiectasis: A Multicenter Cohort Study. Chest. 2017; 151(6): 1247–54.
    1. Shah PL, Mawdsley S, Nash K, Cullinan P, Cole PJ, Wilson R. Determinants of chronic infection with Staphylococcus aureus in patients with bronchiectasis. The European respiratory journal. 1999; 14(6): 1340–4.
    1. Tan WC, Hague CJ, Leipsic J, Bourbeau J, Zheng L, Li PZ, et al. Findings on Thoracic Computed Tomography Scans and Respiratory Outcomes in Persons with and without Chronic Obstructive Pulmonary Disease: A Population-Based Cohort Study. PloS one. 2016; 11(11): e0166745.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する